Delivery Order SPE2DB20D3101-SPE2DB25FRRA7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,135.08 to AmerisourceBergen Drug Corp for KERENDIA 20 MG tablets (30-count package) on September 3, 2025, with an ultimate completion date of September 4, 2025. This firm fixed-price contract, which was competitively awarded with no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $20,324.97 for Kerendia 10 mg tablets (90-count) on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing pharmaceutical...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on September 29, 2025, for the supply of Kerendia 10 mg tablets (30-count units) with a ceiling value of $1,212.13. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 30, 2025. The award is being performed from the contractor's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $3,708.36 to AmerisourceBergen Drug Corp for Kerendia 10 mg tablets (30-count packages) on June 18, 2025, with completion targeted for June 20, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and is being fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $3,524.88 by the Defense Logistics Agency (DLA) on July 28, 2025, for the supply of Kerendia 10 mg tablets (30-count units). This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 29, 2025, to be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $5,589.39 delivery order to AmerisourceBergen Drug Corp for KERENDIA 10 mg tablets (90 count) with a completion date of July 18, 2025. This contract was competitively awarded with no set-aside designation and utilizes firm fixed price terms. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical distributor serving federal healthcare...
- The Defense Logistics Agency awarded a $8,996.13 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Kerendia 20 mg tablets (30-count units). This firm fixed-price, competitively awarded contract is scheduled for completion by June 2, 2025, with performance at the vendor's Conshohocken, Pennsylvania location. The award represents a non-set-aside delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 30, 2025, for the supply of Kerendia 20 mg tablets (30-count packaging) with a ceiling value of $10,329.51. This firm fixed price delivery order, which represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical, is scheduled for completion by September 2, 2025. The award was competitively awarded with no set-aside designation and will be...
- The Defense Logistics Agency awarded a delivery order valued at $17,656.81 to AmerisourceBergen Drug Corp for the supply of Kerendia 10 mg tablets (30-count units) under a firm fixed price contract. The award, issued on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a non-competitive delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,688.67 to AmerisourceBergen Drug Corp for the supply of Kerendia 20 mg tablets (30-count) on September 22, 2025, with an ultimate completion date of September 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child order under AmerisourceBergen Drug Corp's significant...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRRA7Delivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency valued at $6,210.90 for KERENDIA 10 mg tablets (30-count supply). This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery order is scheduled for completion by July 28, 2025, with performance occurring at the company's corporate office location in Conshohocken, Pennsylvania. KERENDIA (finerenone) is a nonsteroidal mineralocorticoid receptor antagonist used in the treatment of chronic kidney disease, particularly in patients with type 2 diabetes. This award reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting military and federal healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to supply a comprehensive range of branded and generic medications across multiple therapeutic domains, positioning it as a key vendor for the Defense Health Agency and other government healthcare organizations through the DLA's pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 7/25/25 |